DOCSLIB.ORG

Generated by SRI International Pathway Tools Version 25.0

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Generated by SRI International Pathway Tools Version 25.0 D2r18Cyc: Loktanella sp. D2R18 Cellular Overview glutamate glutamate asn asn spermidine cefoperazone gln uracil spermidine spermidine spermidine spermidine 4-amino-2-methyl-5- 4-amino-2-methyl-5- 4-amino-2-methyl-5- putrescine putrescine glucosyl-oleandomycin asp asp xanthine putrescine putrescine putrescine putrescine putrescine putrescine a dipeptide pyrimidinemethanol pyrimidinemethanol pyrimidinemethanol 4-amino-2-methyl-5- gln gln pyrimidinemethanol Spermidine predicted ABC predicted ABC predicted ABC Multidrug Glutamate/ Glutamate/ Glutamine Putrescine Putrescine ABC predicted predicted predicted predicted Putrescine Putrescine ABC-type transporter of 4- transporter of 4- transporter of 4- Hydroxymethylpyrimidine resistance glutamine/ glutamine/ transport Uracil- transport transporter ABC ABC ABC ABC transport transport dipeptide amino-2-methyl-5- amino-2-methyl-5- amino-2-methyl-5- ABC transporter, protein aspartate/ aspartate/ ATP- xanthine ATP- permease transporter transporter transporter transporter system system transport pyrimidinemethanol pyrimidinemethanol pyrimidinemethanol norM asparagine asparagine binding permease binding component potC of spermidine/ of spermidine/ of spermidine/ of spermidine/ permease permease system, protein protein (TC_3.A.1.11.1) putrescine putrescine putrescine putrescine 4-amino-2-methyl-5- cefoperazone 4-amino-2-methyl-5- 4-amino-2-methyl-5- 4-amino-2-methyl-5- pyrimidinemethanol glucosyl-oleandomycin glutamate glutamate xanthine spermidine spermidine spermidine spermidine putrescine putrescine a dipeptide pyrimidinemethanol pyrimidinemethanol pyrimidinemethanol asn asn uracil putrescine spermidine gln putrescine putrescine putrescine putrescine asp asp putrescine gln gln Cofactor, Prosthetic Group, Electron Carrier, and Vitamin Biosynthesis Fatty Acid and Lipid Biosynthesis superpathway of glycolysis and the Entner-Doudoroff pathway C1 Compound Utilization and Assimilation UDP-N-acetyl-α-D- a [3-methylcrotonoyl- GlcNAc-1,6- a peptidoglycan 1-stearoyl- 3-oxo-2-(cis-2'-pentenyl) an N-terminal- (S)-3- (S)-3-hydroxy-(7Z) (11Z)-(S)-3- purine nucleotides degradation II (aerobic) Nucleoside and Nucleotide Degradation cob(II)alamin- a long-chain 2,3,4- an apo-[LYS2 L-2- an acyl-[acyl- ditrans,octacis- methylmalonyl- γ a (3Z)-dec-3-enoyl-[acp] a malonyl-[acp] biotin sn-glycerol CO 5'-deoxy-5'-fluoroadenosine -cyclopentane-1-(3R- a peptide β L-methionyl-L- a purine 2'- 4-tyrosol hydroxytetradecanoyl- hydroxyhexadec- superpathway of geranylgeranyl cob(II)yrinate a,c- pyridoxal 5'-phosphate biosynthesis I palmitate biosynthesis II (bacteria and plants) Amine and Polyamine Biosynthesis D-glucopyranose superpathway of pyrimidine superpathway of purine deoxyribonucleosides degradation guanosine nucleotides ATP [CblC-CblD saturated fatty acid coenzyme A muramoyl-L-alanyl- - D-alanyl-D-alanine CoA-carboxylase]-L-lysine anhMurNAc- dimer with undecaprenyldiphospho- -alanine -hexadecenoyl-CoA polyisoprenoid biosynthesis (E. coli) [2Fe-2S] iron-sulfur cluster biosynthesis cob(II)yrinate a,c-diamide superpathway of tetrahydrofolate biosynthesis superpathay of heme b superpathway of adenosylcobalamin salvage from cobinamide I thiamine salvage IV (yeast) biotin biosynthesis from 5-methoxybenzimidazolyl adenosylcobamide palmitoleate phosphatidylglycerol fatty acid elongation -- saturated (Kdo) -lipid A formaldehyde oxidation aminoadipyl-carrier-protein] γ carrier protein] diphosphate biosynthesis II (via MEP) 2 deoxyribonucleosides degradation degradation II formaldehyde oxidation CoA mutase Long-chain-fatty- Holo-[acyl-carrier D-glutamyl-L-lysine Biotin--protein ligase L-Ala- -D-Glu- pentapeptide 3-phosphate N-acetyl-(N- Carbon monoxide Purine nucleoside hydroxybutanoyl)-CoA seryl-[protein] deoxyribonucleoside Alcohol CoA 11-enoyl-CoA diamide biosynthesis I biosynthesis II (late 8-amino-7-oxononanoate I biosynthesis from adenosylcobinamide-GDP biosynthesis I (plastidic) 6-phosphate VII (THF pathway) complex] UDP-N- 3-oxoacyl-[acyl- 1-acyl-sn-glycerol- Enoyl-CoA Xaa-Pro Gamma- Methionine 3-hydroxyacyl- Enoyl-CoA biosynthesis from glutamate biosynthesis I (from biosynthesis I Cob(I)alamin acid--CoA ligase (EC 6.3.4.9, EC 6.3.4.10, DAP-D-AlaN-acetylmuramoyl- stems (meso- dehydrogenase: phosphorylase Purine dehydrogenase, D-glyceraldehyde (early cobalt insertion) D-erythrose glycine betaine biosynthesis 2'-deoxycytidine II (glutathione-dependent) protein] synthase acetylmuramoylalanyl- carrier-protein] 3-phosphate acetylglucosaminyl) aminopeptidase aminobutyrate:alpha- aminopeptidase hydratase predicted pyruvate cobalt incorporation) thiamine an acetoacetyl-[acp] (5Z)-dodec-5-enoate) α α AMP adenosyltransferase (EC 6.2.1.3): Long- EC 6.3.4.11, EC L-alanine (EC 2.4.2.1): hydratase [isoleucine nucleoside CoA IPP L-cysteine desulfurase 4-phosphate cob(II)inamide -Kdo-(2->4)- - putrescine biosynthesis I 2'-deoxyguanosine (EC 2.7.8.7): Holo- diaminopimelateN-acetylmuramoyl- acyltransferase muramoyl-L-alanyl- Carbon monoxide (EC 3.4.13.9) (EC 3.4.11.18) zinc containing [isoleucine ABC 3-phosphate uroporphyrinogen-III 8-amino-7-oxononanoate 5-methoxybenzimidazole DHAP an acetoacetyl-[acp] I (Gram-negative bacteria) formaldehyde D-glutamyl-2,6- synthase, KASI degradation] ketoglutarate dehydrogenase uroporphyrinogen-III GTP glu a (5Z)-dodec- Kdo-(2->6)-lipid IV GMP formaldehyde (EC 2.5.1.17): chain-fatty-acid- [acyl-carrier protein] 6.3.4.15): G1RHH-1824 amidase (EC containing)L-alanine γ-D-isoglutaminyl- dehydrogenase Purine nucleoside phosphorylase (EC 1.1.1.1) thiamine thiamine Adenosylmethionine-8- Glycerol-3- A 5-nucleotidase SurE (EC purine ribonucleosides degradation diaminopimelate--D- (EC 2.3.1.41): (EC 2.3.1.51): 1- (EC 4.2.1.17) / 3- : Xaa-Pro aminotransferase : Methionine (EC 1.1.1.35): 3- degradation] transporter 1-deoxy-D- Uroporphyrinogen- glutamate- Cob(I)alamin 3-oxoacyl-[acyl-carrier 5-enoyl-[acp] Cytidine 2'-deoxyadenosine 5-nucleotidase SurE (EC Cob(I)alamin -CoA ligase (EC 3.5.1.28): N- amidase (EC β medium chain phosphorylase (EC (EC 2.4.2.1) : Alcohol Isopentenyl- Cysteine Uroporphyrinogen- Thiaminase II amino-7-oxononanoate Nicotinate-nucleotide-- choline 3.1.3.5): 5-nucleotidase Purine nucleoside synthase (EC alanyl-D-alanine ligase 3-oxoacyl-[acyl- Biotin--protein acyl-sn-glycerol- N-( -D-asparaginyl)Cell division hydroxyacyl-CoA aminopeptidase (EC 2.6.1.19): Gamma- aminopeptidase hydroxyacyl-CoA (EC 4.2.1.17) / 3- of thiamine xylulose 5- III methyltransferase tRNA ligase: adenosyltransferase (EC protein] reductase (EC 3-oxoacyl- phosphate α arg deaminase 3.1.3.5): 5-nucleotidase adenosyltransferase acetylmuramoyl- 3.5.1.28): N- : Purine dehydrogenase, diphosphate desulfurase III methyltransferase GTP (EC 3.5.99.2): dimethylbenzimidazole -Kdo-(2->4)- Choline dehydrogenase a 5,10- Long-chain-fatty- (EC 6.3.2.10): UDP-N- carrier-protein] ligase (EC 6.3.4.9, 3-phosphate -L-lysyl-D-alanineprotein FtsI Carbon monoxide Purine nucleoside (EC 3.4.13.9) CDS (EC 3.4.11.18) hydroxyacyl-CoA phosphate 4-phospho- aminotransferase 1.1.1.100): G1RHH-1018 [acyl-carrier- dehydrogenase Biosynthetic arginine SurE (EC 3.1.3.5) CDS (EC 3.5.4.5) thymidine phosphorylase SurE (EC 3.1.3.5) CDS 4'-phosphopantetheinyl dehydrogenase aminobutyrate:alpha- nucleoside dehydrogenase (EC 2.1.1.107): delta- (EC 2.1.1.107): cyclohydrolase G1RHH-1889 2.5.1.17): Cob(I)alamin phosphoribosyltransferase α-Kdo-(2->6)- methylenetetrahydrofolate S-(hydroxymethyl) (EC L-alanine acetylmuramoyl- dehydrogenase phosphorylase zinc containing (EC dehydrogenase (EC 2.8.1.7) Thiaminase II (EC 2.6.1.62): protein] [NAD(P)+] (EC (EC 1.1.99.1): G1RHH-1942 Glucose-6- IMP : Cytidine (EC 2.4.2.1): adenosine acid--CoA ligase transferase entD acetylmuramoylalanyl- synthase, EC 6.3.4.10, EC 1-acyl-sn-glycerol- [Peptidoglycan (EC 1.1.1.35) / 3- Xaa-Pro ketoglutarate Methionine (EC Thiamin ABC synthase Uroporphyrinogen- isomerase Uroporphyrinogen-III I (EC 3.5.4.16) [+ 2 isozymes] D-erythronate adenosyltransferase (EC (EC 2.4.2.21): G1RHH-2709 [+ 3 isozymes] (lauroyl)-lipid IV decarboxylase (EC 5'-nucleotidase (EC Adenosine deaminase 5'-nucleotidase (EC glutathione amidase (EC L-alanine small chain phosphorylase , SufS (EC 3.5.99.2) CDS A ATP:Cob(I)alamin (EC 6.2.1.3): Long- D-glutamyl-2,6- 6.3.4.11, EC 6.3.4.15) synthetase] (EC 2.4.2.1): (EC 1.1.1.35) / Glu Adenosylmethionine-8- 1.1.1.94): Glycerol- Choline dehydrogenase phosphate 1- GMP Thymidine Purine nucleoside Methylenetetrahydrofolate (EC 2.7.8.-); 3-oxoacyl-[acyl- 3-phosphate hydroxybutyryl-CoA aminopeptidase aminopeptidase Alcohol thiamine transporter, thiamine (EC 2.2.1.7) III methyltransferase (EC 5.3.3.2): methyltransferase (EC type 2: GTP an L-glutamyl-[tRNA ] synthase, a 3-oxoacyl-[acp] 4.1.1.19): G1RHH-2085 3.1.3.5): G1RHH-2543 deaminase (EC 3.5.4.4): 3.1.3.5): G1RHH-2543 S-(hydroxymethyl) amidase (EC Gamma- (EC subfamily: ATP:Cob(I)alamin amino-7-oxononanoate 5-methoxybenzimidazole (EC 1.1.99.1): Choline dehydrogenase phosphorylase phosphorylase (EC tRNA-specific adenosine- dehydrogenase adenosyltransferase chain-fatty-acid- Holo-[acyl-carrier : Biotin--protein N-acetylmuramoyl- acyltransferase (EC 2.4.1.129) Purine nucleoside epimerase (EC dehydrogenase Enoyl-CoA 3-hydroxybutyryl- transmembrane : 1-deoxy-D- (EC a (3R)-3-hydroxybutanoyl-[acp] KASI (EC 3-phosphate agmatine Inosine-5'-monophosphate (EC 3.5.4.5) Adenosine deaminase guanosine UDP-N- carrier-protein] Carbon monoxide (EC 3.4.11.9) aminobutyrate:alpha- (EC 3.4.11.18) Isopentenyl- Cysteine [+ 2 isozymes] cyclohydrolase chorismate
Load more

Recommended publications
  • Systems and Chemical Biology Approaches to Study Cell Function and Response to Toxins
    Dissertation submitted to the Combined Faculties for the Natural Sciences and for Mathematics of the Ruperto-Carola University of Heidelberg, Germany for the degree of Doctor of Natural Sciences Presented by MSc. Yingying Jiang born in Shandong, China Oral-examination: Systems and chemical biology approaches to study cell function and response to toxins Referees: Prof. Dr. Rob Russell Prof. Dr. Stefan Wölfl CONTRIBUTIONS The chapter III of this thesis was submitted for publishing under the title “Drug mechanism predominates over toxicity mechanisms in drug induced gene expression” by Yingying Jiang, Tobias C. Fuchs, Kristina Erdeljan, Bojana Lazerevic, Philip Hewitt, Gordana Apic & Robert B. Russell. For chapter III, text phrases, selected tables, figures are based on this submitted manuscript that has been originally written by myself. i ABSTRACT Toxicity is one of the main causes of failure during drug discovery, and of withdrawal once drugs reached the market. Prediction of potential toxicities in the early stage of drug development has thus become of great interest to reduce such costly failures. Since toxicity results from chemical perturbation of biological systems, we combined biological and chemical strategies to help understand and ultimately predict drug toxicities. First, we proposed a systematic strategy to predict and understand the mechanistic interpretation of drug toxicities based on chemical fragments. Fragments frequently found in chemicals with certain toxicities were defined as structural alerts for use in prediction. Some of the predictions were supported with mechanistic interpretation by integrating fragment- chemical, chemical-protein, protein-protein interactions and gene expression data. Next, we systematically deciphered the mechanisms of drug actions and toxicities by analyzing the associations of drugs’ chemical features, biological features and their gene expression profiles from the TG-GATEs database.
    [Show full text]
  • The Janus-Like Role of Proline Metabolism in Cancer Lynsey Burke1,Innaguterman1, Raquel Palacios Gallego1, Robert G
    Burke et al. Cell Death Discovery (2020) 6:104 https://doi.org/10.1038/s41420-020-00341-8 Cell Death Discovery REVIEW ARTICLE Open Access The Janus-like role of proline metabolism in cancer Lynsey Burke1,InnaGuterman1, Raquel Palacios Gallego1, Robert G. Britton1, Daniel Burschowsky2, Cristina Tufarelli1 and Alessandro Rufini1 Abstract The metabolism of the non-essential amino acid L-proline is emerging as a key pathway in the metabolic rewiring that sustains cancer cells proliferation, survival and metastatic spread. Pyrroline-5-carboxylate reductase (PYCR) and proline dehydrogenase (PRODH) enzymes, which catalyze the last step in proline biosynthesis and the first step of its catabolism, respectively, have been extensively associated with the progression of several malignancies, and have been exposed as potential targets for anticancer drug development. As investigations into the links between proline metabolism and cancer accumulate, the complexity, and sometimes contradictory nature of this interaction emerge. It is clear that the role of proline metabolism enzymes in cancer depends on tumor type, with different cancers and cancer-related phenotypes displaying different dependencies on these enzymes. Unexpectedly, the outcome of rewiring proline metabolism also differs between conditions of nutrient and oxygen limitation. Here, we provide a comprehensive review of proline metabolism in cancer; we collate the experimental evidence that links proline metabolism with the different aspects of cancer progression and critically discuss the potential mechanisms involved. ● How is the rewiring of proline metabolism regulated Facts depending on cancer type and cancer subtype? 1234567890():,; 1234567890():,; 1234567890():,; 1234567890():,; ● Is it possible to develop successful pharmacological ● Proline metabolism is widely rewired during cancer inhibitor of proline metabolism enzymes for development.
    [Show full text]
  • Amino Acid Disorders 105
    AMINO ACID DISORDERS 105 Massaro, A. S. (1995). Trypanosomiasis. In Guide to Clinical tions in biological fluids relatively easy. These Neurology (J. P. Mohrand and J. C. Gautier, Eds.), pp. 663– analyzers separate amino acids either by ion-ex- 667. Churchill Livingstone, New York. Nussenzweig, V., Sonntag, R., Biancalana, A., et al. (1953). Ac¸a˜o change chromatography or by high-pressure liquid de corantes tri-fenil-metaˆnicos sobre o Trypanosoma cruzi in chromatography. The results are plotted as a graph vitro: Emprego da violeta de genciana na profilaxia da (Fig. 1). The concentration of each amino acid can transmissa˜o da mole´stia de chagas por transfusa˜o de sangue. then be calculated from the size of the corresponding O Hospital (Rio de Janeiro) 44, 731–744. peak on the graph. Pagano, M. A., Segura, M. J., DiLorenzo, G. A., et al. (1999). Cerebral tumor-like American trypanosomiasis in Most amino acid disorders can be diagnosed by acquired immunodeficiency syndrome. Ann. Neurol. 45, measuring the concentrations of amino acids in 403–406. blood plasma; however, some disorders of amino Rassi, A., Trancesi, J., and Tranchesi, B. (1982). Doenc¸ade acid transport are more easily recognized through the Chagas. In Doenc¸as Infecciosas e Parasita´rias (R. Veroesi, Ed.), analysis of urine amino acids. Therefore, screening 7th ed., pp. 674–712. Guanabara Koogan, Sa˜o Paulo, Brazil. Spina-Franc¸a, A., and Mattosinho-Franc¸a, L. C. (1988). for amino acid disorders is best done using both South American trypanosomiasis (Chagas’ disease). In blood and urine specimens. Occasionally, analysis of Handbook of Clinical Neurology (P.
    [Show full text]
  • Preclinical Evaluation of Protein Disulfide Isomerase Inhibitors for the Treatment of Glioblastoma by Andrea Shergalis
    Preclinical Evaluation of Protein Disulfide Isomerase Inhibitors for the Treatment of Glioblastoma By Andrea Shergalis A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Medicinal Chemistry) in the University of Michigan 2020 Doctoral Committee: Professor Nouri Neamati, Chair Professor George A. Garcia Professor Peter J. H. Scott Professor Shaomeng Wang Andrea G. Shergalis [email protected] ORCID 0000-0002-1155-1583 © Andrea Shergalis 2020 All Rights Reserved ACKNOWLEDGEMENTS So many people have been involved in bringing this project to life and making this dissertation possible. First, I want to thank my advisor, Prof. Nouri Neamati, for his guidance, encouragement, and patience. Prof. Neamati instilled an enthusiasm in me for science and drug discovery, while allowing me the space to independently explore complex biochemical problems, and I am grateful for his kind and patient mentorship. I also thank my committee members, Profs. George Garcia, Peter Scott, and Shaomeng Wang, for their patience, guidance, and support throughout my graduate career. I am thankful to them for taking time to meet with me and have thoughtful conversations about medicinal chemistry and science in general. From the Neamati lab, I would like to thank so many. First and foremost, I have to thank Shuzo Tamara for being an incredible, kind, and patient teacher and mentor. Shuzo is one of the hardest workers I know. In addition to a strong work ethic, he taught me pretty much everything I know and laid the foundation for the article published as Chapter 3 of this dissertation. The work published in this dissertation really began with the initial identification of PDI as a target by Shili Xu, and I am grateful for his advice and guidance (from afar!).
    [Show full text]
  • Yeast Genome Gazetteer P35-65
    gazetteer Metabolism 35 tRNA modification mitochondrial transport amino-acid metabolism other tRNA-transcription activities vesicular transport (Golgi network, etc.) nitrogen and sulphur metabolism mRNA synthesis peroxisomal transport nucleotide metabolism mRNA processing (splicing) vacuolar transport phosphate metabolism mRNA processing (5’-end, 3’-end processing extracellular transport carbohydrate metabolism and mRNA degradation) cellular import lipid, fatty-acid and sterol metabolism other mRNA-transcription activities other intracellular-transport activities biosynthesis of vitamins, cofactors and RNA transport prosthetic groups other transcription activities Cellular organization and biogenesis 54 ionic homeostasis organization and biogenesis of cell wall and Protein synthesis 48 plasma membrane Energy 40 ribosomal proteins organization and biogenesis of glycolysis translation (initiation,elongation and cytoskeleton gluconeogenesis termination) organization and biogenesis of endoplasmic pentose-phosphate pathway translational control reticulum and Golgi tricarboxylic-acid pathway tRNA synthetases organization and biogenesis of chromosome respiration other protein-synthesis activities structure fermentation mitochondrial organization and biogenesis metabolism of energy reserves (glycogen Protein destination 49 peroxisomal organization and biogenesis and trehalose) protein folding and stabilization endosomal organization and biogenesis other energy-generation activities protein targeting, sorting and translocation vacuolar and lysosomal
    [Show full text]
  • Amino Acid Disorders
    471 Review Article on Inborn Errors of Metabolism Page 1 of 10 Amino acid disorders Ermal Aliu1, Shibani Kanungo2, Georgianne L. Arnold1 1Children’s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; 2Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, MI, USA Contributions: (I) Conception and design: S Kanungo, GL Arnold; (II) Administrative support: S Kanungo; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: E Aliu, GL Arnold; (V) Data analysis and interpretation: None; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Georgianne L. Arnold, MD. UPMC Children’s Hospital of Pittsburgh, 4401 Penn Avenue, Suite 1200, Pittsburgh, PA 15224, USA. Email: [email protected]. Abstract: Amino acids serve as key building blocks and as an energy source for cell repair, survival, regeneration and growth. Each amino acid has an amino group, a carboxylic acid, and a unique carbon structure. Human utilize 21 different amino acids; most of these can be synthesized endogenously, but 9 are “essential” in that they must be ingested in the diet. In addition to their role as building blocks of protein, amino acids are key energy source (ketogenic, glucogenic or both), are building blocks of Kreb’s (aka TCA) cycle intermediates and other metabolites, and recycled as needed. A metabolic defect in the metabolism of tyrosine (homogentisic acid oxidase deficiency) historically defined Archibald Garrod as key architect in linking biochemistry, genetics and medicine and creation of the term ‘Inborn Error of Metabolism’ (IEM). The key concept of a single gene defect leading to a single enzyme dysfunction, leading to “intoxication” with a precursor in the metabolic pathway was vital to linking genetics and metabolic disorders and developing screening and treatment approaches as described in other chapters in this issue.
    [Show full text]
  • Low Proline Diet in Type I Hyperprolinaemia
    Arch Dis Child: first published as 10.1136/adc.46.245.72 on 1 February 1971. Downloaded from Archives of Disease in Childhood, 1971, 46, 72. Low Proline Diet in Type I Hyperprolinaemia J. T. HARRIES, A. T. PIESOWICZ,* J. W. T. SEAKINS, D. E. M. FRANCIS, and 0. H. WOLFF From The Hospital for Sick Children, and the Institute of Child Health, University of London Harries, J. T., Piesowicz, A. T., Seakins, J. W. T., Francis, D. E. M., and Wolff, 0. H. (1971). Archives of Disease in Childhood, 46, 72. Low proline diet in type I hyperprolinaemia. A diagnosis of Type I hyperprolinaemia was made in a 7-month-old infant who presented with hypocalcaemic convulsions and malabsorp- tion. The plasma levels of proline were grossly raised and the urinary excretion of proline, hydroxyproline, and glycine was increased; neurological development was delayed and there were associated abnormalities of the electroencephalogram, renal tract, and bones. Restriction of dietary proline at the age of 9 months resulted in a prompt fall of plasma levels of proline to normal, and a low proline diet was continued until the age of 27 months when persistence of the biochemical defect was shown. During the period of dietary treatment, growth was satisfactory, mental development improved, and the electroencephalogram, and the renal, skeletal, and intestinal abnormalities disappeared. Proline should be regarded as a 'semi-essential' amino acid in the growing infant. Hyperprolinaemia, appearing in several members balance can be maintained on a proline-free diet copyright. of a family was first described by Scriver, Schafer, (Rose et al., 1955), and therefore the amino acid is and Efron in 1961.
    [Show full text]
  • Proline Metabolism in Glucagon Treated Rats
    PROLINE CATABOLISM IN LIVER by © Michael Roland Haslett A thesis submitted to the School of Graduate Studies in partial fulfilment of the requirements for the degree of Master of Science Department of Biochemistry Memorial University of Newfoundland and Labrador 2009 St. John's Newfoundland and Labrador, Canada Abstract The goal of this work was to localize one of the enzymes involved in proline oxidation, 111-pyrroline-5-carboxylate dehydrogenase (P5CDh) and to gain an understanding of the factors affecting proline catabolism in rat liver. In this regard we performed a systematic subcellular localization for P5CDh and studied proline catabolism in response to dietary protein and exogenous glucagon. Our results indicate that P5CDh is located solely in mitochondria in rat liver. With respect to factors affecting proline catabolism we observed that rats fed a diet containing excess protein (45% casein) display a 1.5 fold increase in activity of P5CDh and proline oxidase (PO), and a 40% increase in flux through the pathway resulting in complete oxidation of proline in isolated mitochondria. We also observed that rats administered exogenous glucagon exhibit a 2 fold increase in PO activity and a 1.5 fold increase in P5CDh activity, and a 2 fold increase in flux through the pathway resulting in complete oxidation of proline in 14 14 isolated mitochondria. C02 production from C-proline in the isolated nonrecirculating perfused rat liver was also elevated 2 fold in the glucagon treated rat. We also studied the transport of proline into isolated hepatocytes and observed a 1.5 fold increase in the transport of proline in rats given exogenous glucagon.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2003/0082511 A1 Brown Et Al
    US 20030082511A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0082511 A1 Brown et al. (43) Pub. Date: May 1, 2003 (54) IDENTIFICATION OF MODULATORY Publication Classification MOLECULES USING INDUCIBLE PROMOTERS (51) Int. Cl." ............................... C12O 1/00; C12O 1/68 (52) U.S. Cl. ..................................................... 435/4; 435/6 (76) Inventors: Steven J. Brown, San Diego, CA (US); Damien J. Dunnington, San Diego, CA (US); Imran Clark, San Diego, CA (57) ABSTRACT (US) Correspondence Address: Methods for identifying an ion channel modulator, a target David B. Waller & Associates membrane receptor modulator molecule, and other modula 5677 Oberlin Drive tory molecules are disclosed, as well as cells and vectors for Suit 214 use in those methods. A polynucleotide encoding target is San Diego, CA 92121 (US) provided in a cell under control of an inducible promoter, and candidate modulatory molecules are contacted with the (21) Appl. No.: 09/965,201 cell after induction of the promoter to ascertain whether a change in a measurable physiological parameter occurs as a (22) Filed: Sep. 25, 2001 result of the candidate modulatory molecule. Patent Application Publication May 1, 2003 Sheet 1 of 8 US 2003/0082511 A1 KCNC1 cDNA F.G. 1 Patent Application Publication May 1, 2003 Sheet 2 of 8 US 2003/0082511 A1 49 - -9 G C EH H EH N t R M h so as se W M M MP N FIG.2 Patent Application Publication May 1, 2003 Sheet 3 of 8 US 2003/0082511 A1 FG. 3 Patent Application Publication May 1, 2003 Sheet 4 of 8 US 2003/0082511 A1 KCNC1 ITREXCHO KC 150 mM KC 2000000 so 100 mM induced Uninduced Steady state O 100 200 300 400 500 600 700 Time (seconds) FIG.
    [Show full text]
  • Degruyter Chem Chem-2021-0032 347..357 ++
    Open Chemistry 2021; 19: 347–357 Research Article Belgin Sever, Mehlika Dilek Altıntop*, Yeliz Demir, Cüneyt Türkeş, Kaan Özbaş, Gülşen Akalın Çiftçi, Şükrü Beydemir*, Ahmet Özdemir A new series of 2,4-thiazolidinediones endowed with potent aldose reductase inhibitory activity https://doi.org/10.1515/chem-2021-0032 received December 2, 2020; accepted February 9, 2021 1 Introduction Abstract: In an effort to identify potent aldose reductase Type 2 diabetes (T2D) is a chronic life-threatening disease (AR) inhibitors, 5-(arylidene)thiazolidine-2,4-diones (1–8), characterized by abnormally high blood glucose levels which were prepared by the solvent-free reaction of 2,4- resulting from impaired response of target tissues to thiazolidinedione with aromatic aldehydes in the presence insulin (insulin resistance) and/or progressively reduced in vitro of urea, were examined for their AR inhibitory function of pancreatic β cells. The global burden of T2D is -( - - - - activities and cytotoxicity. 5 2 Hydroxy 3 methylbenzyli increasing considerably, and therefore there is an urgent ) - - (3) dene thiazolidine 2,4 dione was the most potent AR need to develop safe and potent antidiabetic agents [1–5]. inhibitor in this series, exerting uncompetitive inhibition Polyol pathway is a two-step metabolic pathway K ± with a i value of 0.445 0.013 µM. The IC50 value of in which glucose is reduced to sorbitol, which is then 3 fi - compound for L929 mouse broblast cells was deter converted to fructose. The abnormally activated polyol mined as 8.9 ± 0.66 µM, pointing out its safety as an AR pathway has been reported to participate in the patho- inhibitor.
    [Show full text]
  • And URSPRUNG(1966)
    GENETICS OF OCTANOL DEHYDROGENASE IN DROSOPHILA METZIP+ SARAH BEDICHEK PIPKIN Homrd Uniuersity, Washington, D.C.20001 Received October 11, 1967 CTANOL dehydrogenase (ODH) was studied in Drosophila melanogaster first by URSPRUNGand LEONE(1965) and distinguished from alcohol de- hydrogenase by COURTRIGHT,IMBERSKI, and URSPRUNG(1966). The neotropical species Drosophila metzii is polymorphic for complex octanol dehydrogenase patterns which will be shown to depend on two distinct structural genes, ODH,, apparently homologous with the locus studied by COURTRIGHTet al. (1966), and ODH,, responsible for a more slowly migrating isozyme. The ODH loci are un- linked, and variants display unifactorial inheritance. The ODH molecule is con- sidered at least a dimer but probably a tetramer. Isozyme formation can involve combinations of polypeptides produced by either or both of the two structural genes. Genetic evidence will be presented indicating that egg or embryonic and imaginal ODH isozyme patterns depend on the same structural genes. MATERIALS AND METHODS Single flies were assayed in crude homogenates with 1-octanol as substrate, using the agar gel electrophoresis method, with formazan staining according to the method of DR.H. URSPRUNG (1x5). Modifications of the method for the present work included grinding of single flies in a drop of glass distilled water in specially prepared small homogenizers and allowing the electro- phoresis to proceed at 25Ov for forty minutes instead of half an hour. Enzyme assays for the genetic analysis were made on single females aged 4 to 6 days. The smaller males do not provide sufficient enzyme for reliable single fly analysis. Flies for experimental crosses were reared in pair matings on a medium of corn meal-Karo-Brewer’s yeast #2019 (Standard Brands).
    [Show full text]
  • Gene Expression in Buccal Keratinocytes with Emphasis on Carbonyl Metabolism
    From the Department of Medical Biochemistry and Biophysics Karolinska Institutet, Stockholm, Sweden GENE EXPRESSION IN BUCCAL KERATINOCYTES WITH EMPHASIS ON CARBONYL METABOLISM Claudia A. Staab Stockholm 2008 All previously published papers were reproduced with permission from the publisher. Published by Karolinska Institutet. Printed by [name of printer] © Claudia A. Staab, 2008 ISBN 978-91-7409-127-4 Printed by 2008 Gårdsvägen 4, 169 70 Solna Une sortie, c'est une entrée que l'on prend dans l'autre sens. Boris Vian ABSTRACT The inner lining of the cheek, the buccal mucosa, is a target for air-borne, dietary and tobacco usage-derived carcinogens, but also interesting from a drug delivery point of view. Cancer arising in the buccal epithelium, buccal squamous cell carcinoma (BSCC), often diagnosed at a late disease stage, is highly aggressive and recurrent, emphasizing the need for novel approaches in diagnosis and therapy. An in vitro model for human buccal carcinogenesis consisting of normal buccal keratinocytes (NBK) and two transformed cell lines of buccal origin was applied to explore mechanisms of buccal carcinogenesis, tumor marker and drug target expression. Two-dimensional gel electrophoresis, DNA microarray analysis, and the application of three bioinformatics programs for data mining allowed for the identification of multiple established and potential novel markers for BSCC, including tumor promoter/suppressor genes. Furthermore, post-confluent culture of NBK in absence and presence of fetal bovine serum was successfully used to induce terminal squamous differentiation (TSD) to various extents and thus enrich for different strata of the epithelium. Here, expression and activity of carbonyl-metabolizing enzymes (CMEs) were assessed in view of their multiple roles in phase I biotransformation.
    [Show full text]